Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110062

Cell Surface Differentiation Antigens of the Malignant T Cell in Sezary Syndrome and Mycosis Fungoides

Barton F. Haynes, Paul Bunn, Dean Mann, Charles Thomas, George S. Eisenbarth, John Minna, and Anthony S. Fauci

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Haynes, B. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Bunn, P. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Mann, D. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Thomas, C. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Eisenbarth, G. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Minna, J. in: PubMed | Google Scholar

Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205

Immunology Branch and the National Cancer Institute-Veterans Administration Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205 and Washington, D.C. 20422

Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710

Find articles by Fauci, A. in: PubMed | Google Scholar

Published February 1, 1981 - More info

Published in Volume 67, Issue 2 on February 1, 1981
J Clin Invest. 1981;67(2):523–530. https://doi.org/10.1172/JCI110062.
© 1981 The American Society for Clinical Investigation
Published February 1, 1981 - Version history
View PDF
Abstract

Using a panel of monoclonal antibodies and rabbit heteroantisera, we have studied the cell surface markers of peripheral blood (PB) Sezary cells from six patients with mycosis fungoides or Sezary syndrome, disease grouped within the spectrum of cutaneous T cell lymphomas (CTCL). Furthermore, we have studied two cell lines (Hut 78 and Hut 102) derived from malignant Sezary T cells from CTCL patients. The monoclonal antibody 3A1 defines a major human PB T cell subset (85% of PB T cells) while the antigen defined by the monoclonal antibody 4F2 is present on a subset (70%) of activated PB T cells and on circulating PB monocytes.

In contrast to normal subjects in whom 60-70% of circulating PB mononuclear cells were 3A1+ T cells, PB mononuclear cells from six CTCL patients studied had an average of only 10.6±3.2% 3A1+ T cells. Whereas 85% of E-rosette positive cells from normal individuals were 3A1+, virtually all E-rosette positive T cells from the Sezary patients were 3A1-. Two patients with high numbers of circulating Sezary T cells had both aneuploid and diploid PB T cell populations present; after separation of PB T cells into 3A1+ and 3A1- cell suspensions, all 3A1- cells were found to be aneuploid. In contrast to normal resting PB T cells which were 4F2-, all PB Sezary cells were 4F2+, suggesting a state of activation. The 3A1 antigen was on a variety of acute lymphoblastic leukemia T cell lines (HSB-2, RPMI-8402, MOLT4, CEM) but was absent on the Hut 78 and Hut 102 Sezary T cell lines.

Using rabbit anti-human T and anti-human Ia (p23, 30) antisera, we found that all malignant Sezary PB cells tested were killed by anti-T cell antiserum plus complement but not by anti-Ia plus complement. In contrast, Sezary cell lines Hut 78 and 102, were killed by both anti-T cell antiserum and anti-Ia plus complement.

Similar to 3A1- normal PB T cells, 3A1- Sezary PB T cells proliferated poorly to phytohemagglutinin and concanavalin A. However, 3A1- Sezary T cells were able to provide T cell help towards pokeweed mitogen-induced in vitro B cell immunoglobulin synthesis, an immunoregulatory function limited to 3A1+ T cells in normal subjects.

Thus, the 3A1 antigen is present on 85% of normal PB T cells, and on most T-acute lymphoblastic leukemia lines tested; in contrast the 3A1 antigen is not present on the majority of circulating malignant Sezary PB T cells nor on T cell lines derived from malignant Sezary T cells. The lack of expression of the 3A1 antigen may be associated with malignant transformation of T cells in CTCL and may be an important marker for tracing the clonal origin of the malignant Sezary T cell.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 523
page 523
icon of scanned page 524
page 524
icon of scanned page 525
page 525
icon of scanned page 526
page 526
icon of scanned page 527
page 527
icon of scanned page 528
page 528
icon of scanned page 529
page 529
icon of scanned page 530
page 530
Version history
  • Version 1 (February 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts